Amorfix is an emerging theranostics company formed in January 2004, focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins are prevalent. These include Transmissible Spongiform Encephalopathies, such as Bovine Spongiform Encephalopathy and the human form variant Creutzfeldt-Jakob Disease, as well as degenerative diseases such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Parkinson's Disease. Amorfix Life Sciences provides a service, the Amorfix Aggregated A? Assay (A4), which detects the presence of aggregated A? in standard animal models of AD several months before conventional microscopic procedures, and hence can accelerate the preclinical screening of new treatments for AD.